New Publication in the Lancet: Two-Year Study in Over 1,500 Patients Compares Boehringer Ingelheim Corporation and Eli Lilly and Company's Trajenta® (Linagliptin) to the Commonly Prescribed Sulphonylurea Glimepiride
INGELHEIM, Germany--(BUSINESS WIRE)--EX US & UK. -- Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with Type 2 Diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly fewer hypoglycaemic events and resulted in relative weight loss of 2.7 kg compared to glimepiride.1 The publication reports on a two-year, randomised, double-blind study in 1,552 patients evaluating the efficacy of linagliptin compared to glimepiride as measured by a reduction in HbA1c from baseline in patients uncontrolled on metformin alone.1